Evidence map›Paper›PMID 34222684›Full record

ArticleBiochemistry and biophysics reports2021

Depletion of Kruppel-like factor 15 sensitized gliomas to temozolomide cytotoxicity through

Xinjuan Qu, Xuelai Liu, Yumei Zhang, Zhan Shi, Xiaohua Wang

Open access · goldAbstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. KLF14 inhibits tumor progression via FOSL1 in glioma.Biochemistry and biophysics reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Xinjuan QuDepartment of Neurosurgery, Linyi Hospital of Traditional Chinese Medicine, Shandong, 276002, China.
Xuelai LiuDepartment of Neurosurgery, Linyi Hospital of Traditional Chinese Medicine, Shandong, 276002, China.
Yumei ZhangDepartment of Neurology, Linyi Hospital of Traditional Chinese Medicine, Shandong, 276002, China.
Zhan ShiThe Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, 210002, China.
Xiaohua WangDepartment of General Internal Medicine, Linyi People's Hospital, Shandong, 276003, China.
Linyi City Chinese Medicine Hospital · CNLinyi People's Hospital · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Temozolomide (TMZ)-based chemotherapy is a standard strategy for gliomas, although chemoresistance remains a major therapeutic challenge. The chemical mechanism by which TMZ induces cell death is DNA methylation, leading to double-stranded breaks (DSBs) and thus to apoptosis. However, TMZ-induced N6-meG sites are efficiently repaired and mediated by the DNA repair protein

Indexed as

ChemoresistanceDNA damage RepairGiomasKrupple-like factor 15O6-methylguanine-DNA methyl-TransferaseTranscription activator

Identifiers

PMID34222684
PMCPMC8242961
OpenAlexW3173549113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.